Hospital
Cumberland County Hospital System INC
Cumberland County Hospital System INC was paid $2.70M by Medicaid between Jan 2018 and Dec 2024, across 80 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 25% of everything it billed.
33Billing provider infoCUMBERLAND COUNTY HOSPITAL SYSTEM INC
FAYETTEVILLE, NC 28301
FAYETTEVILLE, NC 28301
33aNPI1982607115assigned 05/23/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.70M
24GClaims113,010
24DCodes billed80
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#70 of 92
Median peer was paid$11.47M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FISER, JOSEPH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,223 | $376K | |
| 2019 | 25,963 | $364K | |
| 2020 | 7,929 | $176K | |
| 2021 | 9,976 | $245K | |
| 2022 | 15,724 | $441K | |
| 2023 | 17,087 | $550K | |
| 2024incomplete | 16,108 | $553K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 25% | 17,880 | 15,384 | $680K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 14% | 12,583 | 10,802 | $369K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 12% | 1,461 | 973 | $338K |
| 87428 | 8.7% | 3,515 | 3,095 | $234K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 5,465 | 4,712 | $200K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 6.1% | 6,026 | 5,017 | $166K |
| 81025 | 3.5% | 11,212 | 9,671 | $95K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.5% | 471 | 438 | $68K |
| 71046 | Radiologic examination, chest; 2 views | 2.5% | 1,370 | 1,164 | $67K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.1% | 3,558 | 3,186 | $57K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.9% | 1,191 | 1,027 | $51K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.2% | 31 | 26 | $32K |
68 more codes
| V2632 | Posterior chamber intraocular lens | 1.1% | 1,352 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,353 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,065 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,065 | $26K |
| 81002 | <1% | 7,152 | $25K | |
| 87070 | <1% | 2,324 | $22K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,400 | $18K |
| 84439 | <1% | 2,296 | $15K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 381 | $13K |
| J3490 | Unclassified drugs | <1% | 4,185 | $12K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,854 | $10K |
| 80053 | Comprehensive metabolic panel | <1% | 1,293 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 256 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 359 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 144 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,234 | $7K |
| 0353U | <1% | 269 | $6K | |
| 85027 | <1% | 1,113 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 54 | $5K |
| A9270 | Non-covered item or service | <1% | 1,622 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,033 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 393 | $5K |
| 87088 | <1% | 472 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 119 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 483 | $4K |
| 86376 | <1% | 355 | $4K | |
| 87210 | <1% | 873 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 69 | $4K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,693 | $3K |
| 11043 | <1% | 24 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,587 | $2K |
| 81003 | <1% | 627 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,407 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 19 | $2K |
| 73130 | <1% | 15 | $2K | |
| 77072 | <1% | 36 | $1K | |
| 84146 | <1% | 77 | $1K | |
| 73562 | <1% | 14 | $1K | |
| 80061 | Lipid panel | <1% | 130 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 116 | $855.32 |
| 83690 | <1% | 127 | $821.59 | |
| 86255 | <1% | 86 | $780.52 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 1,381 | $601.59 |
| 82043 | <1% | 151 | $569.59 | |
| 83516 | <1% | 67 | $556.92 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 19 | $518.66 |
| 82570 | <1% | 155 | $516.00 | |
| 87807 | <1% | 31 | $503.40 | |
| 82784 | <1% | 65 | $451.62 | |
| 84484 | <1% | 63 | $445.35 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 37 | $363.18 |
| 82670 | <1% | 18 | $356.04 | |
| 87077 | <1% | 59 | $349.20 | |
| 82947 | <1% | 290 | $332.61 | |
| 83001 | <1% | 18 | $301.08 | |
| 83002 | <1% | 18 | $300.04 | |
| 86800 | <1% | 25 | $277.48 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 48 | $249.26 |
| J2704 | Injection, propofol, 10 mg | <1% | 32 | $238.37 |
| 82550 | <1% | 44 | $236.95 | |
| 83519 | <1% | 19 | $202.08 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 47 | $186.35 |
| 82565 | <1% | 52 | $185.92 | |
| 87186 | <1% | 15 | $128.38 | |
| 82150 | <1% | 15 | $114.43 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18 | $99.90 |
| 82552 | <1% | 18 | $72.07 | |
| 87205 | <1% | 16 | $47.79 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISER, JOSEPH (VP MANAGED CARE AND REVENUE CYCLE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.